Ascendis Pharma AS (ASND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ascendis Pharma AS (ASND) has a cash flow conversion efficiency ratio of -0.434x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($70.67 Million) by net assets ($-162.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ascendis Pharma AS - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Ascendis Pharma AS for a breakdown of total debt and financial obligations.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euronext N.V.
PA:ENX
|
0.018x |
|
H WORLD GROUP DL-00001
F:CL4
|
0.141x |
|
Yara International ASA
OL:YAR
|
0.217x |
|
Jacobs Solutions Inc.
NYSE:J
|
0.082x |
|
Zhejiang Juhua Co Ltd
SHG:600160
|
0.042x |
|
ZTO Express (Cayman) Inc
F:ZTOA
|
0.049x |
|
Woori Financial Group Inc
NYSE:WF
|
0.235x |
|
Futu Holdings Limited
F:6FHA
|
0.035x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Ascendis Pharma AS (ASND) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-162.75 Million | $51.77 Million | -0.318x | -110.98% |
| 2024-12-31 | $-105.71 Million | $-306.20 Million | 2.897x | -9.70% |
| 2023-12-31 | $-145.70 Million | $-467.36 Million | 3.208x | +270.42% |
| 2022-12-31 | $263.35 Million | $-495.70 Million | -1.882x | -298.24% |
| 2021-12-31 | $883.63 Million | $-417.65 Million | -0.473x | -45.98% |
| 2020-12-31 | $838.71 Million | $-271.55 Million | -0.324x | -9.88% |
| 2019-12-31 | $597.11 Million | $-175.94 Million | -0.295x | +40.55% |
| 2018-12-31 | $280.05 Million | $-138.80 Million | -0.496x | +2.43% |
| 2017-12-31 | $187.21 Million | $-95.10 Million | -0.508x | -49.08% |
| 2016-12-31 | $176.61 Million | $-60.18 Million | -0.341x | +5.67% |
| 2015-12-31 | $120.33 Million | $-43.47 Million | -0.361x | +10.08% |
| 2014-12-31 | $45.81 Million | $-18.40 Million | -0.402x | -140.12% |
| 2013-12-31 | $6.30 Million | $6.31 Million | 1.001x | +338.99% |
| 2012-12-31 | $1.56 Million | $-652.00K | -0.419x | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more